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Early local invasion by astrocytoma cells results in
tumor recurrence even after apparent total surgical
resection, leading to the poor prognosis associated
with malignant astrocytomas. Proteolytic enzymes
have been implicated in facilitating tumor cell inva-
sion and the current study was designed to character-
ize the expression of the cysteine proteinase cathep-
sin S (CatS) in astrocytomas and examine its potential
role in invasion. Immunohistochemical analysis of
biopsies demonstrated that CatS was expressed in
astrocytoma cells but absent from normal astrocytes,
oligodendrocytes, neurones and endothelial cells. Mi-
croglial cells and macrophages were also positive.
Assays of specific activity in 59 astrocytoma biopsies
confirmed CatS expression and in addition demon-
strated that the highest levels of activity were ex-
pressed in grade IV tumors. CatS activity was also
present in astrocytoma cells in vitro and the extracel-
lular levels of activity were highest in cultures derived
from grade IV tumors. In vitro invasion assays were
carried out using the U251MG cell line and the inva-
sion rate was reduced by up to 61% in the presence
of the selective CatS inhibitor 4-Morpholineurea-Leu-
HomoPhe-vinylsulphone. We conclude that CatS ex-
pression is up-regulated in astrocytoma cells and pro-
vide evidence for a potential role for CatS in invasion.
(Am J Pathol 2003, 163:175–182)
Astrocytomas are the commonest primary brain tumors
and within this group the malignant grade III and IV
tumors predominate (anaplastic astrocytomas and glio-
blastomas). Despite their non-metastatic nature, progno-
sis is poor because tumor infiltration of surrounding brain
leads to recurrence even after apparently radical sur-
gery. Multiple stereotactic biopsies of astrocytomas have
demonstrated isolated tumor cells at considerable dis-
tances from the main tumor mass,1 and recent investiga-
tions2 have shown that tumor cells may be cultured from
histologically normal brain at a distance greater than 4
cm from the gross tumor. Astrocytoma invasion is an
active process that involves interactions with the host
extracellular matrix (ECM), proteolytic modification of the
ECM, and migration of the tumor cells into the modified
matrix.3 Members of the metalloproteinase, serine pro-
teinase, and cysteine proteinase superfamilies have
been linked to glioma invasion.4
The cysteine proteinase cathepsin B (CatB) is ex-
pressed in gliomas in vitro5 and immunohistochemical
studies have demonstrated its presence in astrocytomas
and glioblastomas in contrast to its absence from astro-
cytes in normal brain.6,7 The expression and activity of
CatB is higher in anaplastic astrocytomas and glioblas-
tomas compared with low-grade tumors and normal
brain8 and high levels of CatB are positively correlated
with poor survival.9 Human glioblastoma cell lines also
exhibit higher levels of CatB expression than lower grade
astrocytomas10 and the functional relevance of the en-
zyme is confirmed by a marked reduction in in vitro inva-
siveness of a glioblastoma cell line transfected with anti-
sense CatB cDNA.11 There is evidence of altered
trafficking of CatB in glioblastomas, with a redistribution
of enzyme to the cell periphery.12 In addition, a potential
role in invasion has been suggested by high levels at the
tumor periphery and in infiltrating cells.6 The closely re-
lated cysteine proteinase cathepsin L (CatL) has also
been implicated in glioblastoma invasion in an in vitro
model.13
Although much of the attention on cysteine proteinases
in cancer has focused on CatB and CatL, another mem-
ber of the family, cathepsin S (CatS), is also capable of
degrading ECM macromolecules such as laminin, colla-
gens, elastin, and chondroitin sulphate proteoglycan
(CSPG).14 Furthermore, it is markedly more stable than
either CatB or CatL at extracellular pH,15 a property that
is compatible with a role in extracellular proteolysis. Ca-
thepsin S expression has predominantly been associated
with cells of monocyte-macrophage lineage. Functions
ascribed to CatS include degradation of the MHC class II
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chaperone II before peptide loading in the endosomal
compartment16,17,18 and processing of the amyloid pre-
cursor protein.19 Secreted macrophage-derived cysteine
proteinases (including CatS) are implicated in ECM re-
modeling in both pathological20 and physiological con-
ditions.14 Inflammatory mediators increase CatS secre-
tion from macrophages leading to ECM protein
degradation.14 Growth factors such as basic fibroblast
growth factor (bFGF) have been shown to up-regulate
CatS expression.21 These properties of inducibility, ca-
pacity to degrade extracellular macromolecules, and sta-
bility at neutral pH are consistent with a role in tumor
invasion. To date, expression of CatS has not been char-
acterized in brain tumors and the current project is de-
signed to assess the expression of CatS in human astro-
cytoma biopsies and cell cultures.
Materials and Methods
Cell Culture
The G-CCM cell line was initiated from a human ana-
plastic astrocytoma.22 The CB 10923 and the U251MG
cell lines (American Type Culture Collection, Rockville,
MD) were derived from human glioblastomas multiforme.
All other cell cultures were derived from brain tumor
biopsy specimens from the Regional Neurosurgery Unit
of the Royal Victoria Hospital and were used experimen-
tally within 5 to 10 passages. Cultures were tested regu-
larly for mycoplasma using the Hoechst dye-binding
method24 and were found to be negative. Cultures were
maintained in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 20 mmol/L glutamine and
10% fetal calf serum. All cell culture media and reagents
were purchased from Gibco BRL, Paisley, Scotland.
Cathepsin S Assay
Cells for CatS assay were harvested by scraping from
confluent T25 flasks, resuspended in 1 ml of Hanks’
balanced salt solution (HBSS) and sedimented at 1000
g for 5 minutes. The cell pellet was made up to 250 l in
MES buffer (50 mmol/L, pH 6.0) containing 0.1% TritonX-
100. Complete cell disruption was ensured by sonication
(MSE Soniprep150, Sanyo-Gallen-Kamp, Loughboro,
Leicestershire, UK). The protein concentration of the ho-
mogenate was determined using the BCA reagent kit
(Pierce, Rockford, IL, USA) and aliquots were diluted to a
concentration of 25 to 50 mg/L for CatS assay.
Tissue samples used in this study were derived from
diagnostic biopsies received from the Regional Neuropa-
thology Service, Royal Victoria Hospital, with the approval
of the local ethics committee. All surgical samples were
snap-frozen immediately after removal and stored at
70°C. Tissue samples of astrocytomas (7 grade I, 4
grade II, 15 grade III, 33 grade IV) were homogenized in
MES lysis buffer (0.2 mol/L, pH 6.0) containing 0.1%
TritonX-100 and sonicated (MSE Soniprep 150). The pro-
tein concentration of the homogenate was determined
using the BCA reagent kit (Pierce) and aliquots were
diluted to a concentration of 2 to 5 mg/ml and the super-
natants were used for CatS assay.
CatS activity was assayed using carbobenzoxy-valyl-
valyl-arginyl-N-methylcoumarylamide (VVR) as substrate.
Before assay, homogenates were incubated in 100
mmol/L phosphate buffer (pH 7.5) for 1 hour at 37°C to
inactivate cathepsins B and L, after which the pH was
returned to pH 6.0 using 0.5 mol/L of MES buffer. Assays
were performed in 96-well microtitre plates in the pres-
ence of 1 mmol/L dithiothreitol, 200 mmol/L ethylenedia-
minetetraacetate, and 100 mol/L VVR in 200 mmol/L
MES buffer, pH 6.0. Incubation at 37°C was continued for
90 minutes and the reaction was terminated by addition
of 100 mmol/L of acetate buffer, pH 4.3. Fluorescence
generated by release of methylcoumarin (nMec) from the
substrate was read in Perkin Elmer LS50B luminescence
spectrophotometer (Perkin Elmer, Shelton, CT, USA) with
excitation and emission wavelengths of 370 nm and 460
nm, respectively. Each assay was performed on triplicate
samples and controls were included with substrate omit-
ted from the assay. A calibration line was prepared using
nMec, and CatS activity was calculated as nmol nMec
produced/mg protein hour1.1 There was a linear rela-
tionship between relative fluorescence activity and nMec
concentration and the enzyme assay was linear with re-
spect to reaction time and protein content of the cell
homogenate.
For assay of extracellular CatS activity, confluent cul-
tures were maintained for 24 hours in serum-free medium
to obviate the effect of endogenous cysteine proteinase
inhibitors in fetal calf serum. The medium was then re-
moved from the cells and centrifuged at 1000  g for 5
minutes to remove any detached cells before assay.
Aliquots of medium (30 l) were assayed for CatS activity
using the same procedure used for cell homogenates.
Extracellular CatS activity is expressed as nmol nMec
produced/mg cellular protein hour1.1
Reverse Transcription-Polymerase Chain
Reaction and Sequencing
RNA was prepared from confluent astrocytoma cultures
and normal brain using RNAstat 60 (Biogenesis Ltd.,
Poole, Dorset, UK), reverse-transcribed with Maloney
murine leukemia virus (MMLV) reverse transcriptase (Ad-
vanced Biotechnologies, Columbia, MD) and cDNA am-
plified by polymerase chain reaction (PCR). The CatS-
specific primers used for PCR were designed to flank the
CatS coding region and generate a 1002-bp amplicon.
They correspond to positions 158–177 and 1123–1153,
respectively.25
CatS forward primer: 5-atgaaacggctggtttgtgt-3
CatS reverse primer: 5-ctagatttctgggtaagagggaaagc-
tagc-3
The 1001-bp DNA fragment was purified (Gibco) from
the 1% agarose gel and ligated into pIND/V5-His-TOPO
using TA Cloning (InVitrogen, UK). The resulting con-
struct was used to transform TOP10 cells. Positive clones
were selected and plasmid DNA was prepared (Concert
MaxiPrep; Gibco). The fragment was sequenced using
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the dideoxy chain termination method to confirm its iden-
tity with CatS.
Immunocytochemistry
Acetone-fixed cells on coverslips were rehydrated with
PBS for 5 minutes and incubated for 1 hour at room
temperature in goat polyclonal anti-CatS antibody (Santa
Cruz Biotechnologies, Santa Cruz, CA) diluted 1:50 in
PBS. An isotype-matched rabbit IgG negative control
antibody (Dako, Denmark) was used at the same con-
centration as the primary antibody. The coverslips
were washed three times for 5 minutes in PBS before
incubation in fluorescein-isothiocyanate-conjugated
anti-goat antibody diluted 1:50 in PBS for 1 hour and
after three 5-minute washes in PBS were mounted in
Citifluor (0.25 g of 1,4 diazobicyclo-2,2,2-octane, 5 ml
of PBS, 5 ml of glycerol). Nuclei were stained by incu-
bation in 1.3 g/ml of propidium iodide in PBS for 10
seconds, and washed in distilled water before mount-
ing in Citifluor.
Immunohistochemistry
Tissue samples used in this study were derived from
diagnostic biopsies received from the Regional Neuropa-
thology Service. Tissue was fixed in 10% formalin before
embedding in paraffin wax with a Tissue Tek VIP (Miles
Scientific) automated processor. The paraffin blocks
were sectioned at a thickness of 6 m, sections were
dewaxed, rehydrated, and endogenous peroxidase ac-
tivity blocked by a 10-minute incubation in 3% H2O2 in
methanol, followed by a rinse in distilled water. Sections
were subjected to microwave antigen retrieval as previ-
ously described.26 After rinsing in running distilled water,
non-specific binding of secondary antibody was blocked
by incubating in 5% normal rabbit serum for 10 minutes.
Sections were subsequently incubated overnight at 4°C
in anti-CatS antibody at 1:50 dilution. Isotype-matched
rabbit negative-control antibody raised to Aspergillus ni-
ger glucose oxidase was used at 1:200 dilution to achieve
an equivalent primary antibody concentration. Bound an-
tibodies were detected with biotinylated rabbit anti-goat
IgG and streptavidin-biotin-peroxidase complex as pre-
viously described.26
Dual-Labeled Immunofluorescence
Paraffin sections of brain tumor biopsies were incu-
bated overnight at 4°C in anti-CatS antibody at 1:50
dilution. This was then detected by incubating with
biotin-conjugated rabbit anti-goat IgG (1:400 dilution,
30 minutes, RT) followed by 30-minute incubation in
streptavidin peroxidase (1:500 dilution, RT; NEN Sci-
ences, USA) with TBS washes between each step.
Sections were then incubated for 20 minutes at RT in
tetramethylrhodamine tyramide reagent, diluted 1:50 in
amplification reagent (tetramethyl-thodamine tyramide
reagent (TTR); NEN Life Sciences, Boston, MA, USA).
Following further washes in TBS, excess peroxidase
sites were quenched with 1% hydrogen peroxide in
TBS for 15 minutes. The sections were incubated over-
night at 4°C in monoclonal anti-CD68 antibody (Dako)
at 1:50 dilution or in monoclonal anti-glial fibrillary
acidic protein (GFAP) antibody (Dako) at 1:100 dilu-
tion. Sections were then incubated in peroxidase-
conjugated rabbit anti-mouse IgG (1:50 dilution) for 30
minutes followed by 20 minutes incubation in fluores-
cein tyramide reagent, diluted 1:50 in amplification
reagent (fluorescein tyramide reagent (FTR); NEN Life
Sciences) both at RT. Following final washes in TBS,
sections were mounted in Citifluor and viewed with a
Leica TCS/NT confocal microscope equipped with a
krypton/argon laser.
In Vitro Invasion Assay
Invasion assays were performed as previously de-
scribed,27 with variations, using a modified Boyden
chamber (Costar Transwell plates) with 12-m pore
membranes. The membranes were coated with Matrigel
(100 g/cm2) and allowed to dry overnight in a tissue
culture hood; 5  10 U251MG glioblastoma cells were
added to the well in 500 l serum-free medium.
Experiments testing the effect of the CatS inhibitor,
4-Morpholineurea-Leu-HomoPhe-vinylsulphone (LHVS),
a gift from Axys Pharmaceuticals, used medium contain-
ing LHVS at concentrations of 10 nmol/L and 50 nmol/L.
1.5 ml of homologous conditioned growth medium was
added to the lower chamber and triplicate invasion plates
were incubated at 37°C and 5% CO2 for 24 hours. Cells
remaining on the upper surface of the membrane were
removed by wiping and the invaded cells were fixed in
Carnoy’s fixative for 15 minutes.
After drying, the nuclei of the invaded cells on the
lower surface of the membrane were stained with
Hoechst 33258 (50 ng/ml) in HBSS for 30 minutes at room
temperature. The insert was washed twice in PBS and
mounted in Citifluor for microscopic examination. In-
vaded cells were viewed with a Leica DMLB fluorescence
Figure 1. RT-PCR of mRNA extracted from cultures derived from astrocyto-
mas of World Health Organization grade I (1 to 3), World Health Organiza-
tion grade II (4 to 7), World Health Organization grade III (8 and 9), and
World Health Organization grade IV. 10 and 11: RT-PCR of mRNA extracted
from a normal brain sample. 12: PCR, without RT step, of mRNA extracted
from World Health Organization grade IV cell culture to demonstrate the
absence of DNA contamination in the mRNA preparation. 13: Positive control
mRNA sample of 500 bp. 14: Water (negative control). 15: Size markers. 16:
CatS is represented by the fraction of 996 bp.
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microscope. Four digital images of representative fields
from each of the triplicate membranes were taken at a
magnification of 200. Results were expressed as the
mean number of cells present per field.
Results
RT-PCR
mRNA isolated from a range of astrocytoma cell lines was
reverse transcribed and subjected to PCR using primers
specific for sequences flanking the coding region of CatS.
Agarose gel electrophoresis (Figure 1) showed a single
amplicon of a size consistent with CatS (996 bp). After
purification the 996 bp amplicon was cloned, sequenced,
and shown to have complete identity with the sequence of
CatS (GenBank Accession Number M90696).
Immunohistochemistry/Cytochemistry
Thirty-one brain tumor biopsy specimens were examined,
representing all four World Health Organization grades.28
(5 grade I, 10 grade II, 5 grade III, 11 grade IV). In all
cases tumor cells were positive for CatS expression (Fig-
ure 2,A and B). Normal astrocytes and other glial cells
(Figure 2C), neurones (Figure 2C) and endothelial cells
(Figure 2B) were CatS-negative while reactive astrocytes
in zones of gliosis were faintly CatS-positive (Figure 2E).
The intensity of neoplastic astrocyte staining within and
Figure 2. A: CatS immunostaining of World Health Organization grade II
astrocytoma. B: CatS immunostaining of World Health Organization grade IV
astrocytoma (inset shows area of endothelial hyperplasia (e) with CatS-
negative endothelial cells). C: CatS immunostaining of normal brain. n,
neurone; a, astrocyte; o, oligodendrocyte; m, macrophage. D: CD68 staining
of tumor-associated microglia/macrophages in World Health Organization
grade IV astrocytoma (inset shows perivascular macrophages). E: CatS
immunostaining of brain with gliosis from a World Health Organization
grade II astrocytoma (r, reactive astrocyte). Original magnification, 400.
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between grades was variable and there was no correla-
tion between level of expression and tumor grade.
CD68 immunostaining confirmed the presence of cells
of microglia/monocytic origin within tumors (Figure 2D)
and in surrounding brain. Double immunohistochemical
staining for CatS and CD68 revealed expression of CatS
in the CD68-positive microglia/monocytic cells as well as
in CD68-negative tumor cells (Figure 3, A and B). Double
immunohistochemical staining for CatS and GFAP re-
vealed distinct localization of CatS and GFAP within as-
trocytoma cells (Figure 3C). Twenty-one astrocytoma cell
cultures examined were CatS-positive and immunostain-
ing showed a punctate cytoplasmic distribution charac-
teristic of lysosomal localization (Figure 3D). There was
no correlation between the degree of immunostaining
and grade of tumor.
Cathepsin S Activity
Biopsies: CatS activity in tumor lysates varied considerably
between tumors (Figure 4). Astrocytoma grades I to III had
Figure 3. A: Immunostaining of grade IV astrocytoma to show CD68-positive microglia/macrophages (arrows). B: CatS/CD68 dual labeling. Microglia/
macrophages are positive for CatS and CD68 (arrows) whereas astrocytoma cells (arrowheads) are only positive for CatS. C: CatS (red)/GFAP (green) dual
labeling. The lysosomal localization of CatS immunostaining (I) is distinct from that of GFAP which is predominantly within tumor cell foot processes (p). m,
mitotic figure; n, outline of nucleus; bv, blood vessel. D: CatS immunostaining of astrocytoma cells in vitro. Nuclei are counterstained with propidium iodide.
Original magnification, 400.
Figure 4. Specific activity of CatS in lysates derived from biopsies of
astrocytomas I-IV.
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similar ranges of activity; however, while some grade IV
tumors expressed activity levels similar to the lower grades,
almost half of them had markedly higher levels.
Cell Cultures
Activity of CatS was measured in 31 astrocytoma cul-
tures. Intracellular activity was present in all cultures and
within each grade there was considerable variation in
specific activity (Figure 5A). There was no correlation
between CatS activity and grade of the tumor of origin.
All cultures were shown to secrete CatS into the me-
dium and there was a clear trend toward high levels of
secretion in cultures derived from grade IV tumors (Fig-
ure 5B). There was no correlation between secreted CatS
activity and cell-associated activity (Figure 5C).
Invasion Assay
The effect of the CatS inhibitor LHVS29 was assessed
using the U251MG glioblastoma cell line in the Matrigel
invasion assay. Incorporation of 10 nmol/L and 50 nmol/L
LHVS in the medium produced significant decreases
(P  0.0001) in invasion of 49% and 61%, respectively
(Figure 6).
Discussion
Biochemical and immunohistochemical studies of the
cysteine proteinases CatB and CatL have reported their
presence in astrocytomas in contrast to their absence
from astrocytes in normal brain.7 The present investiga-
tion has demonstrated for the first time that the related
cysteine proteinase CatS is also expressed in astrocyto-
mas in vivo and in vitro. Normal astrocytes, however, were
negative for CatS immunoreactivity in agreement with
other studies of CatS in normal brain. Neurones, oligo-
dendrocytes, and endothelial cells were also CatS-neg-
ative. Petanceska30 used in situ hybridization on rat brain
to show that in contrast to the wide distribution of CatB
and CatL, the expression of CatS mRNA is restricted to
monocyte-derived microglial cells. In human brain also,
CatS is not widely distributed.31 In an immunohistochem-
ical study, Lemere et al32 demonstrated the absence of
CatS from normal astrocytes, but in the brain of patients
Figure 5. Specific activity of CatS in astrocytoma cultures (grades I to IV). a:
Intracellular activity. b: Extracellular activity. c: Plot of extracellular CatS
versus intracellular CatS activity for each culture.
Figure 6. In vitro invasion assay. Photomicrographs (magnification, 200)
show Hoechst-stained nuclei of U251MG glioblastoma cells which have
invaded to the lower side of the Matrigel-coated microporous membrane. a:
Control assay. b: 10 nmol/L LHVS incorporated in the invasion assay. c: 50
nmol/L LHVS incorporated in the assay. The histogram is a quantitative
summary of the data. Each assay was performed in triplicate and four fields
were counted in each assay.
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with Down syndrome and Alzheimer’s disease CatS was
up-regulated in a subset of astrocytes and in neurones
with neurofibrillary tangles.
Few studies of CatS in tumors have been carried out,
but in an immunohistochemical survey of soft tissue sar-
comas Wurl et al33 showed that 65% of cases expressed
CatS. CatS expression was associated with poor prog-
nosis and local recurrence. Fernandez et al34 demon-
strated CatS expression at all stages of prostatic carci-
noma progression with no correlation between
expression levels and tumor grade. In a study of lung
cancer, Kos et al35 found higher levels of CatS protein in
tumor tissue when compared with adjacent control tissue,
but in this case the risk of death was higher in patients
with low levels of CatS in the tumor and parenchyma.
Nissler et al36 demonstrated that intracellular pro-CatS in
a lung tumor cell line has twice the half-life of pro-CatS
expressed in human macrophages and that substantial
amounts of pro-CatS were secreted in vitro. The present
immunohistochemical investigation of CatS protein found
up-regulated CatS expression in astrocytoma cells but
did not suggest a positive correlation between CatS ex-
pression level and astrocytoma grade. However, direct
measurement of CatS activity in astrocytoma homoge-
nates indicated highest activity levels in grade IV tumors.
Interpretation of CatS expression data from tumor lysates
is problematic because of the cellular complexity of the
tumor environment, which contains host normal and in-
flammatory cells in addition to tumor cells. We have
shown that normal glial cells, neurones, and endothelial
cells do not express CatS. However, macrophages and
microglia may make significant contributions to the ap-
parent CatS expression of the tumor. CD68/CatS dual
labeling in the current investigation confirms the pres-
ence of considerable numbers of CatS-positive microglia/
macrophages. Astrocytomas characteristically have a
high content of cells of microglial/monocytic origin,37 with
a higher density present in high-grade astrocytomas rel-
ative to low-grade tumors. A positive correlation has been
reported between microglia/monocyte content and astro-
cytoma grade and this may explain the high CatS-spe-
cific activity that we found in many grade IV tumors.38,39
It seems possible that brain microglia and macrophages
may play an active role in tumor invasion rather than
non-specific reaction to tissue injury. This is suggested
by Bettinger et al40 who have shown that microglial cells
promote astrocytoma migration in vitro. The secreted mi-
gration-stimulating factors were not specifically identi-
fied, although growth factors such as transforming
growth factor- were suggested as potential candidates.
However, microglia/macrophages express high levels
of a range of proteolytic enzymes including CatS which
may augment the proteolytic activity of the tumor cells
and promote invasion by modifying the extracellular
matrix.41–43
To assess tumor cell expression and a potential role in
invasion in the absence of other cell types, we have used
astrocytoma cultures. We found no correlation between
intracellular CatS activity and grade of the tumor of origin.
In contrast, extracellular activity, which is likely to be most
relevant to proteolysis associated with the invasive pro-
cess, was significantly elevated in grade IV tumors. The
absence of up-regulation of intracellular enzyme in the
presence of increased secretion may be unexpected, but
a similar situation has been described during macro-
phage activation. Liuzzo et al14 found that lipopolysac-
charide and other inflammatory mediators induced an
increase in CatS secretion while expression of intracellu-
lar CatS mRNA and protein was down-regulated.
Inhibition of CatS activity of U251MG cells with LHVS
resulted in a 60% reduction in invasion, suggesting a
significant role for CatS in the invasive process. Biroc et
al44 observed a comparable 60% reduction in joint tissue/
ECM destruction with oral LHVS administration in a rat
model of rheumatoid arthritis. Local invasion of tumor
cells beyond resection borders is a feature of malignant
astrocytomas leading to recurrence which is largely re-
sponsible for failure of conventional astrocytoma therapy.
Protease inhibitors may therefore offer a method for the
control of proteolytic activity associated with ECM deg-
radation and cell invasion. It is likely that successful
treatment of malignant astrocytoma will involve the appli-
cation of combinatorial therapeutic strategies.
CatS retains optimal activity over a wider pH range (5.0
to 7.5) than CatB and CatL (5.5 to 6.5).15 The broad pH
profile of mature CatS indicates that it would remain
active in the astrocytoma extracellular environment. We
have demonstrated the presence of extracellular CatS
activity in vitro which may reflect either secretion of ma-
ture enzyme or extracellular activation of secreted proen-
zyme by other proteinases. Active CatS in the extracel-
lular environment of astrocytomas may contribute to
degradation of ECM components thereby facilitating the
invasive process.
In summary, this investigation has demonstrated that
CatS is expressed and active in astrocytoma cells. In
addition, we have provided evidence that CatS plays a
role in the invasive process and is therefore a potential
target for anti-invasive therapy.
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